Method for reducing browning and / or degradation reaction of N-acetylneuraminic acid and application

Abstract

The invention discloses a method for improving the stability of an N-acetylneuraminic acid liquid preparation and application, and relates to the field of industrial production. The method comprises adding hyaluronic acid or a salt thereof to the N-acetylneuraminic acid liquid preparation. Preferably, the mass ratio of the N-acetylneuraminic acid to the hyaluronic acid or the salt thereof in the N-acetylneuraminic acid liquid preparation is 1: (0.1-10). The hyaluronic acid or the salt thereof is added into the N-acetylneuraminic acid liquid preparation, so that the browning and degradation problems of the N-acetylneuraminic acid are effectively improved, the effects of the N-acetylneuraminic acid liquid preparation in foods, medicines and cosmetics are ensured, and the hyaluronic acid liquid preparation has a wide application prospect in industrial production.

Description

Technical Field

[0001] The invention relates to the technical field of biochemistry, and in particular to a method and application of reducing the browning and / or degradation reaction of N-acetylneuraminic acid. Background Art

[0002] Sialic acid (SA) is a nine-carbon main chain sugar, the variation of its C-5 determines the core sialic acid structure, and O-substitutions (including acetyl, methyl, lactyl, sulfate and phosphate) on C-4, C-7, C-8 and / or C-9 produce further diversity in the SA family. SA exists in sialic acid sugar conjugates (Sialoglycoconjugates) of some bacteria, viruses, protozoa and fungi, as well as in glycoproteins, glycolipid gangliosides and glycosaminoglycans in mammals and lower vertebrates. In mammalian cells, the most common SA is N-acetylneuraminic acid and N-glycosylneuraminic acid, of which N-glycosylneuraminic acid is completely absent in normal human cells, so sialic acid in the term usually refers to N-acetylneuraminic acid.

[0003] Sialic acid is an important component of oligosaccharides in human milk. Free sialic acid also has nutritional value. Dietary supplementation of free sialic acid in the diet is effective for humans and has safety and tolerance. The content of N-acetylneuraminic acid in the human brain is very high. After the age of 60, the level of sialic acid in the human body begins to decline slowly, and drops sharply after the age of 90. Neurodegenerative diseases are one of the most common diseases associated with aging. Sialic acid is related to Alzheimer's disease (AD) and Parkinson's disease (PD). Studies have shown that the level of N-acetylneuraminic acid in the blood or brain of Alzheimer's patients decreases. After drug treatment, N-acetylneuraminic acid returns to normal levels. In terms of intestinal health, N-acetylneuraminic acid can improve the intestinal absorption of minerals and vitamins and is conducive to the colonization and growth of beneficial bacteria in the intestine. Since N-acetylneuraminic acid has a very strong negative charge, due to the physical effect of opposites attracting each other, minerals with positive charges and some vitamins combine and accumulate with N-acetylneuraminic acid in the intestine, reducing the loss of nutrients and facilitating intestinal absorption. N-acetylneuraminic acid is also one of the main functional active ingredients of bird's nest extract (EBN). Chan et al. from the Hong Kong University of Science and Technology reported that EBN can play a whitening effect by inhibiting tyrosinase activity and reducing melanin production.

[0004] Currently, China, the United States, and the European Union have all evaluated the safety of N-acetylneuraminic acid and approved its release into the market as a safe new food ingredient. Various foods containing N-acetylneuraminic acid have also appeared on the market, including compressed candies, solid beverages, liquid functional beverages, etc.

[0005] High-purity N-acetylneuraminic acid has a wide range of applications, including food, cosmetics and pharmaceuticals. Whether it is in the form of solid or liquid, stability is an important indicator. However, N-acetylneuraminic acid has poor stability, especially in liquid preparations. It is prone to browning and degradation under high temperature conditions. Improving the stability of N-acetylneuraminic acid helps to ensure the efficacy of N-acetylneuraminic acid products and further expand the application range of N-acetylneuraminic acid. Summary of the invention

[0006] In order to solve the problem that sialic acid, especially N-acetylneuraminic acid, is prone to browning and degradation in liquid preparations, the present invention is proposed, and the specific contents of the present invention are as follows:

[0007] In a first aspect, the present invention provides the use of hyaluronic acid or its salt in inhibiting the degradation of N-acetylneuraminic acid. Further, the molecular weight of the hyaluronic acid or its salt can be selected from 8×10 4 Da-200×10 4 Da, further, the molecular weight is 20×10 4 Da-150×10 4 In some embodiments, the molecular weight of sodium hyaluronate is 8×10 4 Da~200×10 4 Da, for example, can be 8×10 4 Da~200×10 4 Da, for example, can be 8×10 4 Da, 9×10 4 Da, 10×10 4 Da, 11×10 4 Da, 12×10 4 Da, 13×10 4 Da, 14×10 4 Da, 15×10 4 Da, 16×10 4 Da, 17×10 4 Da, 18×10 4 Da, 19×10 4 Da, 20×10 4 Da, 21×10 4 Da, 22×10 4 Da, 23×10 4 Da, 24×10 4 Da, 25×10 4 Da, 26×10 4 Da, 27×10 4 Da, 28×10 4 Da, 29×10 4Yes, 30×10 4 Yes, 31×10 4 Yes, 32×10 4 Yes, 33×10 4 Yes, 34×10 4 Yes, 35×10 4 Yes, 36×10 4 Yes, 37×10 4 Yes, 38×10 4 Yes, 39×10 4 Yes, 40×10 4 Yes, 41×10 4 Yes, 42×10 4 Yes, 43×10 4 Yes, 44×10 4 Yes, 45×10 4 Yes, 46×10 4 Yes, 47×10 4 Yes, 48×10 4 Yes, 49×10 4 Yes, 50×10 4 Yes, 51×10 4 Yes, 52×10 4 Yes, 53×10 4 Yes, 54×10 4 Yes, 55×10 4 Yes, 56×10 4 Yes, 57×10 4 Yes, 58×10 4 Yes, 59×10 4 Yes, 60×10 4 Yes, 61×10 4 Yes, 62×10 4 Yes, 63×10 4 Yes, 64×10 4 Yes, 65×10 4 Yes, 66×10 4 Yes, 67×10 4 Yes, 68×10 4 Yes, 69×10 4 Yes, 70×10 4 Yes, 71×10 4 Yes, 72×10 4 Yes, 73×10 4 Yes, 74×10 4 Yes, 75×10 4 Yes, 76×10 4 Yes, 77×104 Yes, 78×10 4 Yes, 79×10 4 Yes, 80×10 4 Yes, 81×10 4 Yes, 82×10 4 Yes, 83×10 4 Yes, 84×10 4 Yes, 85×10 4 Yes, 86×10 4 Yes, 87×10 4 Yes, 88×10 4 Yes, 89×10 4 Yes, 90×10 4 Yes, 91×10 4 Yes, 92×10 4 Yes, 93×10 4 Yes, 94×10 4 Yes, 95×10 4 Yes, 96×10 4 Yes, 97×10 4 Yes, 98×10 4 Yes, 99×10 4 Yes, 100×10 4 Yes, 101×10 4 Yes, 102×10 4 Yes, 103×10 4 Yes, 104×10 4 Yes, 105×10 4 Yes, 106×10 4 Yes, 107×10 4 Yes, 108×10 4 Yes, 109×10 4 Yes, 110×10 4 Yes, 111×10 4 Yes, 112×10 4 Yes, 113×10 4 Yes, 114×10 4 Yes, 115×10 4 Yes, 116×10 4 Yes, 117×10 4 Yes, 118×10 4 Yes, 119×10 4 Yes, 120×10 4 Yes, 121×10 4 Yes, 122×10 4 Yes, 123×10 4Yes, 124×10 4 Yes, 125×10 4 Yes, 126×10 4 Yes, 127×10 4 Yes, 128×10 4 Yes, 129×10 4 Yes, 130×10 4 Yes, 131×10 4 Yes, 132×10 4 Yes, 133×10 4 Yes, 134×10 4 Yes, 135×10 4 Yes, 136×10 4 Yes, 137×10 4 Yes, 138×10 4 Yes, 139×10 4 Yes, 140×10 4 Yes, 141×10 4 Yes, 142×10 4 Yes, 143×10 4 Yes, 144×10 4 Yes, 145×10 4 Yes, 146×10 4 Yes, 147×10 4 Yes, 148×10 4 Yes, 149×10 4 Yes, 150×10 4 Yes, 151×10 4 Yes, 152×10 4 Yes, 153×10 4 Yes, 154×10 4 Yes, 155×10 4 Yes, 156×10 4 Yes, 157×10 4 Yes, 158×10 4 Yes, 159×10 4 Yes, 160×10 4 Yes, 161×10 4 Yes, 162×10 4 Yes, 163×10 4 Yes, 164×10 4 Yes, 165×10 4 Yes, 166×10 4 Yes, 167×10 4 Yes, 168×10 4 Yes, 169×104 Da, 170×10 4 Da, 171×10 4 Da, 172×10 4 Da, 173×10 4 Da, 174×10 4 Da, 175×10 4 Da, 176×10 4 Da, 177×10 4 Da, 178×10 4 Da, 179×10 4 Da, 180×10 4 Da, 181×10 4 Da, 182×10 4 Da, 183×10 4 Da, 184×10 4 Da, 185×10 4 Da, 186×10 4 Da, 187×10 4 Da, 188×10 4 Da, 189×10 4 Da, 190×10 4 Da, 191×10 4 Da, 192×10 4 Da, 193×10 4 Da, 194×10 4 Da, 195×10 4 Da, 196×10 4 Da, 197×10 4 Da, 198×10 4 Da, 199×10 4 Da, 200×10 4 Da or any range therebetween. In some preferred embodiments, the molecular weight of the sodium hyaluronate is 20×10 4 Da~150×10 4 Da.

[0008] In a second aspect of the present invention, a use of hyaluronic acid or a salt thereof in inhibiting the browning of N-acetylneuraminic acid is provided. Further, the molecular weight of the hyaluronic acid or a salt thereof can be selected to be 8×10 4 Da-200×10 4 Da, further, the molecular weight is 20×10 4 Da-150×10 4 In some embodiments, the molecular weight of sodium hyaluronate is 8×10 4 Da~200×104 Yes, for example 8×10 4 Yes~200×10 4 Yes, for example 8×10 4 Yes, 9×10 4 Yes, 10×10 4 Yes, 11×10 4 Yes, 12×10 4 Yes, 13×10 4 Yes, 14×10 4 Yes, 15×10 4 Yes, 16×10 4 Yes, 17×10 4 Yes, 18×10 4 Yes, 19×10 4 Yes, 20×10 4 Yes, 21×10 4 Yes, 22×10 4 Yes, 23×10 4 Yes, 24×10 4 Yes, 25×10 4 Yes, 26×10 4 Yes, 27×10 4 Yes, 28×10 4 Yes, 29×10 4 Yes, 30×10 4 Yes, 31×10 4 Yes, 32×10 4 Yes, 33×10 4 Yes, 34×10 4 Yes, 35×10 4 Yes, 36×10 4 Yes, 37×10 4 Yes, 38×10 4 Yes, 39×10 4 Yes, 40×10 4 Yes, 41×10 4 Yes, 42×10 4 Yes, 43×10 4 Yes, 44×10 4 Yes, 45×10 4 Yes, 46×10 4 Yes, 47×10 4 Yes, 48×10 4 Yes, 49×10 4 Yes, 50×10 4 Yes, 51×10 4 Yes, 52×104 Yes, 53×10 4 Yes, 54×10 4 Yes, 55×10 4 Yes, 56×10 4 Yes, 57×10 4 Yes, 58×10 4 Yes, 59×10 4 Yes, 60×10 4 Yes, 61×10 4 Yes, 62×10 4 Yes, 63×10 4 Yes, 64×10 4 Yes, 65×10 4 Yes, 66×10 4 Yes, 67×10 4 Yes, 68×10 4 Yes, 69×10 4 Yes, 70×10 4 Yes, 71×10 4 Yes, 72×10 4 Yes, 73×10 4 Yes, 74×10 4 Yes, 75×10 4 Yes, 76×10 4 Yes, 77×10 4 Yes, 78×10 4 Yes, 79×10 4 Yes, 80×10 4 Yes, 81×10 4 Yes, 82×10 4 Yes, 83×10 4 Yes, 84×10 4 Yes, 85×10 4 Yes, 86×10 4 Yes, 87×10 4 Yes, 88×10 4 Yes, 89×10 4 Yes, 90×10 4 Yes, 91×10 4 Yes, 92×10 4 Yes, 93×10 4 Yes, 94×10 4 Yes, 95×10 4 Yes, 96×10 4 Yes, 97×10 4 Yes, 98×10 4 Yes, 99×10 4Yes, 100×10 4 Yes, 101×10 4 Yes, 102×10 4 Yes, 103×10 4 Yes, 104×10 4 Yes, 105×10 4 Yes, 106×10 4 Yes, 107×10 4 Yes, 108×10 4 Yes, 109×10 4 Yes, 110×10 4 Yes, 111×10 4 Yes, 112×10 4 Yes, 113×10 4 Yes, 114×10 4 Yes, 115×10 4 Yes, 116×10 4 Yes, 117×10 4 Yes, 118×10 4 Yes, 119×10 4 Yes, 120×10 4 Yes, 121×10 4 Yes, 122×10 4 Yes, 123×10 4 Yes, 124×10 4 Yes, 125×10 4 Yes, 126×10 4 Yes, 127×10 4 Yes, 128×10 4 Yes, 129×10 4 Yes, 130×10 4 Yes, 131×10 4 Yes, 132×10 4 Yes, 133×10 4 Yes, 134×10 4 Yes, 135×10 4 Yes, 136×10 4 Yes, 137×10 4 Yes, 138×10 4 Yes, 139×10 4 Yes, 140×10 4 Yes, 141×10 4 Yes, 142×10 4 Yes, 143×10 4 Yes, 144×10 4 Yes, 145×104 Yes, 146×10 4 Yes, 147×10 4 Yes, 148×10 4 Yes, 149×10 4 Yes, 150×10 4 Yes, 151×10 4 Yes, 152×10 4 Yes, 153×10 4 Yes, 154×10 4 Yes, 155×10 4 Yes, 156×10 4 Yes, 157×10 4 Yes, 158×10 4 Yes, 159×10 4 Yes, 160×10 4 Yes, 161×10 4 Yes, 162×10 4 Yes, 163×10 4 Yes, 164×10 4 Yes, 165×10 4 Yes, 166×10 4 Yes, 167×10 4 Yes, 168×10 4 Yes, 169×10 4 Yes, 170×10 4 Yes, 171×10 4 Yes, 172×10 4 Yes, 173×10 4 Yes, 174×10 4 Yes, 175×10 4 Yes, 176×10 4 Yes, 177×10 4 Yes, 178×10 4 Yes, 179×10 4 Yes, 180×10 4 Yes, 181×10 4 Yes, 182×10 4 Yes, 183×10 4 Yes, 184×10 4 Yes, 185×10 4 Yes, 186×10 4 Yes, 187×10 4 Yes, 188×10 4 Yes, 189×10 4 Yes, 190×10 4Da, 191×10 4 Da, 192×10 4 Da, 193×10 4 Da, 194×10 4 Da, 195×10 4 Da, 196×10 4 Da, 197×10 4 Da, 198×10 4 Da, 199×10 4 Da, 200×10 4 Da or any range therebetween. In some preferred embodiments, the molecular weight of the sodium hyaluronate is 20×10 4 Da~150×10 4 Da.

[0009] Preferably, the application includes inhibiting the degradation and / or browning of N-acetylneuraminic acid caused by high temperature.

[0010] Furthermore, the application includes inhibiting the degradation and / or browning of N-acetylneuraminic acid caused by high temperature in liquid preparations.

[0011] Furthermore, the mass ratio of N-acetylneuraminic acid to hyaluronic acid or its salt is 1:0.1-10, for example, it can be 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 and any range therebetween.

[0012] More preferably, the mass ratio of N-acetylneuraminic acid to hyaluronic acid or its salt is 1:0.3-7.

[0013] In some specific embodiments, the mass concentration of the hyaluronic acid or its salt is 0.1% to 2%, for example, it can be 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.5%, 2.0%, and any range therebetween.

[0014] Preferably, the mass concentration of the hyaluronic acid or its salt is 0.2% to 1.75%.

[0015] In some specific embodiments, the mass concentration of N-acetylneuraminic acid is 0.1% to 1%, for example, it can be 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% and any range therebetween.

[0016] Preferably, the mass concentration of the N-acetylneuraminic acid is 0.2% to 0.5%.

[0017] In a third aspect of the present invention, there is provided a method for reducing the degradation and / or browning of a liquid preparation of N-acetylneuraminic acid in the liquid preparation, characterized in that the method comprises the following steps:

[0018] Hyaluronic acid or a salt thereof is added to a liquid preparation containing N-acetylneuraminic acid.

[0019] Furthermore, the mass ratio of N-acetylneuraminic acid to hyaluronic acid or its salt is 1:0.1-10, for example, it can be 1:0.1, 1:0.2, 1:0.3, 1:0.4, 1:0.5, 1:0.6, 1:0.7, 1:0.8, 1:0.9, 1:1, 1:2, 1:3, 1:4, 1:5, 1:6, 1:7, 1:8, 1:9, 1:10 and any range therebetween.

[0020] More preferably, the mass ratio of N-acetylneuraminic acid to hyaluronic acid or its salt is 1:0.3-7.

[0021] In some specific embodiments, the mass concentration of the hyaluronic acid or its salt is 0.1% to 2%, for example, it can be 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0%, 1.5%, 2.0%, and any range therebetween.

[0022] Preferably, the mass concentration of the hyaluronic acid or its salt is 0.2% to 1.75%.

[0023] In some specific embodiments, the mass concentration of N-acetylneuraminic acid is 0.1% to 1%, for example, it can be 0.1%, 0.2%, 0.3%, 0.4%, 0.5%, 0.6%, 0.7%, 0.8%, 0.9%, 1.0% and any range therebetween.

[0024] Preferably, the mass concentration of the N-acetylneuraminic acid is 0.2% to 0.5%.

[0025] The fourth aspect of the present invention provides a composition prepared by the method.

[0026] The fifth aspect of the present invention provides use of the composition in the preparation of medicines, foods and cosmetics.

[0027] The beneficial effects of the present invention include but are not limited to:

[0028] 1. The present invention adds hyaluronic acid or its salt to the N-acetylneuraminic acid liquid preparation, thereby effectively improving the browning and degradation problems of N-acetylneuraminic acid in the liquid preparation, reducing the loss of N-acetylneuraminic acid content, and ensuring the effect of using the N-acetylneuraminic acid in food, medicine, and cosmetics.

[0029] 2. The method of the present invention is simple in process and provides guarantee for large-scale industrial production. BRIEF DESCRIPTION OF THE DRAWINGS

[0030] The drawings described herein are used to provide a further understanding of the present invention and constitute a part of the present invention. The exemplary embodiments of the present invention and their descriptions are used to explain the present invention and do not constitute an improper limitation of the present invention. In the drawings:

[0031] Figure 1 These are the results of high temperature sterilization of N-acetylneuraminic acid solutions in some examples of the present invention, and from left to right they correspond to experiments numbered 2-3, 2-5, 2-6, 2-8, and 2-1 in the examples. DETAILED DESCRIPTION

[0032] The present application is described in detail below in conjunction with specific embodiments. It should be understood that the present application can be implemented in various forms and should not be limited by the embodiments described herein. On the contrary, these embodiments are provided in order to enable a more thorough understanding of the present application and to fully convey the scope of the present application to those skilled in the art. It should be noted that "including" or "comprising" as mentioned throughout the specification and claims are open-ended terms and should be interpreted as "including but not limited to". The subsequent description of the specification is a preferred embodiment for implementing the present application, but the description is for the purpose of illustrating the general principles of the present application and is not intended to limit the scope of the present application. The scope of protection of the present application shall be subject to that defined by the attached claims.

[0033] Example

[0034] Sodium hyaluronate used in this application and N-acetylneuraminic acid All are from Bloomage Biotechnology Co., Ltd. Other reagents are known products unless otherwise specified.

[0035] Experimental methods

[0036] 1. Color and clarity inspection

[0037] Referring to the first method of clarity test method in Part 4, 0902 of the 2020 edition of the "Chinese Pharmacopoeia", take 5g of the test solution at room temperature and place it in the same tasting cup. The tasting cup is made of colorless and transparent plastic. Place it vertically under the umbrella shed light in a dark room with an illumination of 1000lx, and observe and compare from the same direction.

[0038] 2. Content detection

[0039] (1) Chromatographic conditions: Column: MCI GEL column (8×300 mm, 9 μm);

[0040] Mobile phase: 1% phosphoric acid;

[0041] Flow rate: 0.6 mL / min;

[0042] Injection volume: 20 μL;

[0043] Column temperature: 40°C;

[0044] Detection wavelength: 210nm.

[0045] (2) Preparation of reference solution

[0046] The reference substance is Yuanye Bio B5078-1g, catalog number cas#131-48-6;

[0047] Accurately weigh 100 mg of sialic acid reference substance dried to constant weight, put it into a 100 mL volumetric flask, add water to dissolve and dilute to the scale, mix well, filter through a 0.22 μm filter membrane, and obtain the reference solution.

[0048] (3) Preparation of test solution

[0049] Accurately pipette / weigh 2 ml / 2 g of the test sample into a 10 mL volumetric flask, dilute with water and make up to volume, filter with a 0.22 μm filter membrane to obtain the test sample solution.

[0050] (4) Testing

[0051] Take samples of the reference solution and the test solution respectively, record the chromatograms, and calculate the sialic acid content by the external standard method.

[0052] Example 1 Protective effect of sodium hyaluronate on N-acetylneuraminic acid at different temperatures

[0053] The molecular weight is 80×10 4 The mass concentration of Da sodium hyaluronate in the solution is 0.5%, and the mass concentration of N-acetylneuraminic acid in the solution is 0.1%. After the hyaluronic acid and N-acetylneuraminic acid are mixed and dissolved completely, they are sterilized at 80°C for 20 min, 100°C for 20 min, 110°C for 20 min, and 121°C for 20 min, respectively. After sterilization, the solution color and the change of N-acetylneuraminic acid content in the solution are observed and recorded. Three parallel samples are set for each group, and the content determination results are averaged. The specific operations of each group are shown in Table 1.

[0054] Table 1 Example 1 Liquid preparation group number (30g / portion)

[0055]

[0056] The results are shown in Table 2.

[0057] Table 2 Test results of Example 1

[0058] Group N-acetylneuraminic acid content (mg / ml) color 0 1.00±0.01 Colorless, clear and transparent 0-80 0.96±0.01 Colorless, clear and transparent 0-100 0.94±0.01 Colorless, clear and transparent 0-110 0.56±0.01 Discoloration - Tan 0-121 0.45±0.01 Discoloration - Tan 1 1.00±0.01 Colorless, clear and transparent 1-80 0.98±0.01 Colorless, clear and transparent 1-100 <![CDATA[0.97±0.01 a ]]> Colorless, clear and transparent 1-110 <![CDATA[0.89±0.01 b ]]> Color change-yellow 1-121 <![CDATA[0.86±0.01 c ]]> Color change-yellow

[0059] Note: a is the comparison between 1-100 and 0-100, p < 0.05, with significant difference; b is the comparison between 1-110 and 0-110, p < 0.05, with significant difference; c is the comparison between 1-121 and 0-121, p < 0.05, with significant difference.

[0060] Example 2 Preparation of liquid preparation

[0061] Sodium hyaluronate with different molecular weights and N-acetylneuraminic acid were mixed evenly; the mass concentration of N-acetylneuraminic acid was 0.27%, and the molecular weight of sodium hyaluronate was 8×10 4 Da, 20×10 4 Da, 100×10 4 Da, 150×10 4 Da, the mass concentrations of sodium hyaluronate in the solution were 0.1%, 0.2%, 0.5%, 0.75%, 1%, 1.25%, 1.5%, 1.75%, the addition amounts of the blank control group and each experimental group were as shown in Table 1. After preparation, high temperature wet heat sterilization at 121°C for 20 min was adopted, and the changes in solution color and N-acetylneuraminic acid content before and after sterilization were observed.

[0062] Table 3 Detailed composition of liquid preparation of Example 2 (30 g / portion)

[0063]

[0064]

[0065] The experimental results are shown in Table 4 and Figure 1 shown.

[0066] Table 4 Example 2 test results

[0067]

[0068]

[0069] Note: * Compared with the blank control group, p < 0.05, there is a significant difference.

[0070] Based on the results of the examples, except for group 1-1, the other groups were significantly different from the blank control group. In the application of sodium hyaluronate to protect N-acetylneuraminic acid (mass concentration in solution is 0.27%), when the mass concentration of sodium hyaluronate is 0.1% to 2%, sodium hyaluronate can effectively inhibit the degradation of N-acetylneuraminic acid. When the mass concentration of sodium hyaluronate is 0.2% to 2%, sodium hyaluronate can effectively inhibit the browning reaction of N-acetylneuraminic acid. When the molecular weight of sodium hyaluronate is 8×10 4 Da~200×10 4 Da, sodium hyaluronate has a good protective effect on N-acetylneuraminic acid, and the change of the molecular weight of sodium hyaluronate has little effect on the protective effect of N-acetylneuraminic acid.

[0071] The above description is only an embodiment of the present invention. The protection scope of the present invention is not limited by these specific embodiments, but is determined by the claims of the present invention. For those skilled in the art, the present invention may have various changes and variations. Any modification, equivalent substitution, improvement, etc. made within the technical ideas and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. Use of hyaluronic acid or its salt in inhibiting the degradation of N-acetylneuraminic acid.

2. Application of hyaluronic acid or its salts in inhibiting the browning of N-acetylneuraminic acid.

3. The use according to claim 1 or 2, characterized in that: The mass ratio of the N-acetylneuraminic acid to hyaluronic acid or its salt is 1:0.1-10.

4. The use according to any one of claims 1 to 3, characterized in that: The mass ratio of the N-acetylneuraminic acid to hyaluronic acid or its salt is 1:0.3-7.

5. A method for reducing the degradation and / or browning of N-acetylneuraminic acid in a liquid preparation, characterized in that: The following steps are involved: Hyaluronic acid or a salt thereof is added to a liquid preparation containing N-acetylneuraminic acid.

6. The method according to claim 5, characterized in that The mass ratio of N-acetylneuraminic acid to hyaluronic acid or its salt in the liquid preparation is 1:0.1-10.

7. The method according to claim 5 or 6, characterized in that The mass ratio of N-acetylneuraminic acid to hyaluronic acid or its salt in the liquid preparation is 1:0.3-7.

8. A composition prepared by the method of any one of claims 5 to 7.

Images